Skip to content

The Predictive Value of Lubricin in Patients With Infective Endocarditis

The Predictive Value of Lubricin in Patients With Infective Endocarditis

Status
Enrolling by invitation
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06266741
Enrollment
60
Registered
2024-02-20
Start date
2024-02-11
Completion date
2026-02-20
Last updated
2024-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infective Endocarditis

Keywords

Infective endocarditis, Lubricin, Glycoprotein, Procalcitonin

Brief summary

The main goal of this study is to evaluate the predictability of the disease by measuring the serum lubricin levels in patients with infective endocarditis and in non-patients

Detailed description

Infective endocarditis is a challenging disease with a wide range of clinical presentations, making it difficult to diagnose. Diagnosis primarily relies on clinical suspicion based on symptoms. Blood cultures or other microbial tests confirming the presence of infection and echocardiography are supportive diagnostic tools. Another marker that may become valuable in the near future for diagnosing infective endocarditis is Lubricin. Lubricin, a glycoprotein expressed by the PRG4 gene, has been found to have significantly elevated levels in the plasma of animals with damaged or infected heart valves compared to healthy animals. Furthermore, plasma lubricin levels can potentially serve as a biomarker in situations like endocardial injury and infection. Lubricin and Procalcitonin will be studied from the blood samples routinely collected. During this academic study, procalcitonin and lubricin values will be measured by investigators. Thus, the sensitivity and specificity of the Lubricin parameter in patients with infective endocarditis will be evaluated.

Interventions

DIAGNOSTIC_TESTLubricin

Plasma lubricin levels can potentially serve as a biomarker in situations like endocardial injury and infection.

Sponsors

Aydin Adnan Menderes University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years

Inclusion criteria

* The patient must be between 18 and 65 years old * Patients diagnosed with infective endocarditis according to the Duke criteria

Exclusion criteria

\- The patient being pregnant

Design outcomes

Primary

MeasureTime frameDescription
Valve damage indicative sign in infective endocarditisthrough study completion, an average of 2 yearsConcentration of Lubricin parameter have a determinative role in patients with infective endocarditis

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026